Clinical Trials Logo

Clinical Trial Summary

We propose the novel integration of two echocardiographic technologies - three-dimensional echocardiography using semi-automated right ventricular analysis coupled with the administration of ultrasound enhancing agents - to improve the inter-rater reliability and accuracy of various measures of right ventricular size and function, compared with cardiac MRI.


Clinical Trial Description

Patients with repaired tetralogy of Fallot represent a challenging group of patients with congenital heart disease as they develop progressive right ventricular dilation and failure, increasing the risk for sudden cardiac death and often necessitating pulmonary valve replacement. These patients require close follow-up with serial cardiac imaging; however, the complex three-dimensional structure of these dilated right ventricles renders them difficult to adequately image with traditional two-dimensional echocardiography. Due to these difficulties, cardiac MRI is the current gold standard for assessing right ventricular size and function in these patients. However, cardiac MRI is costly and less accessible for patients than echocardiography. Although initial studies comparing 3D echocardiography with MRI showed that 3D echocardiography underestimates right ventricular size, recent advances in three-dimensional imaging technologies which utilize automated ultrasound "speckle-tracking" and artificial intelligence technology are lessening this inherent bias. Furthermore, the use of commercially-available ultrasound enhancing agents made of lipid microspheres has improved left ventricular endocardial border detection, inter-rater reliability and correlation of 3D echocardiography obtained estimates of left ventricular size and function compared with CMR. However, their use has yet to be applied to the three-dimensional echocardiographic assessment of the right ventricle despite their ability to improve right ventricular endocardial border detection with two-dimensional echocardiography. The investigators propose the novel integration of two echocardiographic technologies - three-dimensional echocardiography using semi-automated right ventricular analysis coupled with the administration of ultrasound enhancing agents - to change the paradigm of how clinicians assess the right ventricles of patients with repaired tetralogy of Fallot. The investigators hypothesize that ultrasound enhancing agents will improve the inter-rater reliability and accuracy of various measures of right ventricular size and function, compared with cardiac MRI, thereby filling an important gap in existing methods for assessing right ventricular function. Lastly, because of the current limitations in assessing right ventricular function in this population, as a secondary aim, the investigators will also assess three-dimensional right ventricular strain -- a novel quantitative surrogate of right ventricular function. Overall Objectives: To shift the paradigm in the assessment of right ventricular size and function by developing a protocol to assess the right ventricles in patients with repaired tetralogy of Fallot by integrating the use of three-dimensional echocardiography with semi-automated right ventricular analysis software with the intravenous administration of ultrasound enhancing agents. Specific Aim 1. To compare the accuracy and inter-rater reliability of 3D echocardiography-based measurements of right ventricular end-diastolic volume, end-systolic volume, and ejection fraction, with and without contrast, with MRI derived values in patients with repaired tetralogy of Fallot. Specific Aim 2. To compare the accuracy and inter-rater reliability of 3D echocardiography measurement of right ventricular strain with MRI derived RV strain in patients with repaired tetralogy of Fallot. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05186415
Study type Interventional
Source Nemours Children's Health System
Contact Matthew J Campbell, MD, MSHP
Phone 3022684102
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date January 2022
Completion date January 2023

See also
  Status Clinical Trial Phase
Completed NCT02534792 - Early Revalvulation After Fallot Repair Improves Clinical Outcome N/A
Completed NCT00536432 - Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot N/A
Completed NCT01941576 - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot N/A
Recruiting NCT03983512 - PULSTA Transcatheter Pulmonary Valve Pre-Approval Study N/A
Recruiting NCT04581668 - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease N/A
Recruiting NCT04713657 - Beta-blocker Administration for Cardiomyocyte Division Phase 1
Completed NCT01762124 - Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV) N/A
Active, not recruiting NCT02161471 - Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance
Recruiting NCT04106479 - NIRS in Congenital Heart Defects - Correlation With Echocardiography
Recruiting NCT03049995 - Stress Echo 2020 - The International Stress Echo Study
Completed NCT02586740 - Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation N/A
Terminated NCT00564993 - Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot Phase 3
Recruiting NCT05122962 - Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
Completed NCT03835494 - Analysis of RV-Dysfunction in Fallot Patients N/A
Not yet recruiting NCT03275844 - Physical Capacity and Activity in Children With Congenital Heart Disease N/A
Recruiting NCT02590679 - Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p Phase 2/Phase 3
Recruiting NCT00155428 - Biomodel in Tetralogy of Fallot N/A
Completed NCT00573066 - Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery Phase 1
Recruiting NCT02980614 - 4D Velocity Mapping of the Heart in rTOF Patients N/A
Active, not recruiting NCT03441971 - Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction N/A